Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.61 |
| ▸ | TK2 | O00142 | 5/20 | 0.59 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.53 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.52 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.48 |
| ▸ | TK1 | P04183 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3633967 | 1.00 | PYGM (0.61) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL614561 | 1.00 | PYGM (0.61) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| Phosphoric Acid SCHEMBL5091060 | 0.96 | DNPH1 (0.58) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL1140108 | 0.90 | PYGM (0.62) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL15798486 | 0.87 | PYGM (0.65) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL29775099 | 0.87 | PYGM (0.45) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL2577629 | 0.86 | PYGM (0.63) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL45508 | 0.86 | PYGM (0.63) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL45507 | 0.86 | PYGM (0.63) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL29184342 | 0.86 | PYGM (0.61) | PYGMTK2TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339990-A1 | RNAi CONJUGATES, PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2020-10-29 | — | — | US | disclosed |
| US-20180273948-A1 | RNAi CONJUGATES, PARTICLES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2018-09-27 | — | — | US | disclosed |
| WO-2017053720-A1 | RNAi CONJUGATES, PARTICLES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2017-03-30 | — | — | WO | disclosed |
| EP-2170924-A2 | 5-BROMO-2'-DEOXY-URIDINE LABELED NUCLEOTIDE TRIPHOSPHATES AND NUCLEIC ACID PROBES AND METHODS OF MAKING AND USING THE SAME | Applera Corporation (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090233366-A1 | COMPOSITION FOR INTRODUCTION OF NUCLEIC ACID | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-2080767-A1 | COMPOSITION FOR INTRODUCTION OF NUCLEIC ACID | Daiichi Sankyo Company, Limited (JP) | 2009-07-22 | — | — | EP | disclosed |
| EP-1782315-A4 | PROGNOSIS OF BREAST CANCER PATIENTS | ROSETTA INPHARMATICS LLC (US) | 2009-06-24 | — | — | EP | disclosed |
| WO-2008157311-A2 | 5-BROMO-2'-DEOXY-URIDINE LABELED NUCLEOTIDE TRIPHOSPHATES AND NUCLEIC ACID PROBES AND METHODS OF MAKING AND USING THE SAME | APPLERA CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| EP-1590433-A4 | DIAGNOSIS AND PROGNOSIS OF BREAST CANCER PATIENTS | ROSETTA INPHARMATICS LLC (US) | 2008-10-01 | — | — | EP | disclosed |
| EP-1782315-A2 | PROGNOSIS OF BREAST CANCER PATIENTS | Rosetta Inpharmatics LLC. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006015312-A2 | PROGNOSIS OF BREAST CANCER PATIENTS | ROSETTA INPHARMATICS LLC (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-1590433-A2 | DIAGNOSIS AND PROGNOSIS OF BREAST CANCER PATIENTS | Rosetta Inpharmatics LLC. (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004065545-A2 | DIAGNOSIS AND PROGNOSIS OF BREAST CANCER PATIENTS | ROSETTA INPHARMATICS LLC. (US) | 2004-08-05 | — | — | WO | disclosed |